PMID- 20145162
OWN - NLM
STAT- MEDLINE
DCOM- 20100426
LR  - 20210103
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Linking)
VI  - 16
IP  - 4
DP  - 2010 Feb 15
TI  - The predictive value of HLA class I tumor cell expression and presence of 
      intratumoral Tregs for chemotherapy in patients with early breast cancer.
PG  - 1272-80
LID - 10.1158/1078-0432.CCR-09-1844 [doi]
AB  - PURPOSE: We hypothesized that T-cell immune interaction affects tumor development 
      and thus clinical outcome. Therefore, we examined the clinical impact of human 
      leukocyte antigen (HLA) class I tumor cell expression and regulatory T-cell 
      (Treg) infiltration in breast cancer. EXPERIMENTAL DESIGN: Our study population 
      (N = 677) is consisted of all early breast cancer patients primarily treated with 
      surgery in our center between 1985 and 1994. Formalin-fixed, paraffin-embedded 
      tumor tissue was immunohistochemically stained using HCA2, HC10, and Foxp3 
      monoclonal antibodies. RESULTS: HLA class I expression was evaluated by combining 
      results from HCA2 and HC10 antibodies and classified into three groups: loss, 
      downregulation, and expression. Remarkably, only in patients who received 
      chemotherapy, both presence of Treg (P = 0.013) and higher HLA class I expression 
      levels (P = 0.002) resulted in less relapses, independently of other variables. 
      Treg and HLA class I were not of influence on clinical outcome in patients who 
      did not receive chemotherapy. CONCLUSIONS: We showed that HLA class I and Treg 
      affect prognosis exclusively in chemotherapy-treated patients and are therefore 
      one of the few predictive factors for chemotherapy response in early breast 
      cancer patients. Chemotherapy may selectively eliminate Treg, thus enabling CTLs 
      to kill tumor cells that have retained HLA class I expression. As a consequence, 
      HLA class I and Treg can predict response to chemotherapy with high 
      discriminative power. These markers could be applied in response prediction to 
      chemotherapy in breast cancer patients.
FAU - de Kruijf, Esther M
AU  - de Kruijf EM
AD  - Departments of Surgery, Leiden University Medical Center, Leiden, The 
      Netherlands.
FAU - van Nes, Johanna G H
AU  - van Nes JG
FAU - Sajet, Anita
AU  - Sajet A
FAU - Tummers, Quirijn R J G
AU  - Tummers QR
FAU - Putter, Hein
AU  - Putter H
FAU - Osanto, Susanne
AU  - Osanto S
FAU - Speetjens, Frank M
AU  - Speetjens FM
FAU - Smit, Vincent T H B M
AU  - Smit VT
FAU - Liefers, Gerrit Jan
AU  - Liefers GJ
FAU - van de Velde, Cornelis J H
AU  - van de Velde CJ
FAU - Kuppen, Peter J K
AU  - Kuppen PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100209
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/*immunology/pathology
MH  - Female
MH  - Histocompatibility Antigens Class I/*biosynthesis
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - T-Lymphocytes, Regulatory/*immunology
EDAT- 2010/02/11 06:00
MHDA- 2010/04/27 06:00
CRDT- 2010/02/11 06:00
PHST- 2010/02/11 06:00 [entrez]
PHST- 2010/02/11 06:00 [pubmed]
PHST- 2010/04/27 06:00 [medline]
AID - 1078-0432.CCR-09-1844 [pii]
AID - 10.1158/1078-0432.CCR-09-1844 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2010 Feb 15;16(4):1272-80. doi: 10.1158/1078-0432.CCR-09-1844. 
      Epub 2010 Feb 9.